Blumont Pharma Limited

POWER SEARCH PRICING

SOLUTIONS

blumont pharma limited Company Information

Company Number

05643716

Next Accounts

Sep 2025

Directors

Palaniswamy Sunderraj

Jane Whitton

View All

Shareholders

manoj prabu janaki ponnusamy

jane whitton

Group Structure

View All

Industry

Non-specialised wholesale trade

Registered Address

23 moortown close, grantham, lincolnshire, NG31 9GG

Website

www.blumontpharma.com

blumont pharma limited Estimated Valuation

£2.1m

Pomanda estimates the enterprise value of BLUMONT PHARMA LIMITED at £2.1m based on Net Assets of £788.7k and 2.62x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Blumont Pharma Limited is a live company located in lincolnshire, NG31 9GG with a Companies House number of 05643716. It operates in the non-specialised wholesale trade sector, SIC Code 46900. Founded in December 2005, it's largest shareholder is manoj prabu janaki ponnusamy with a 90% stake. Blumont Pharma Limited is a mature, small sized company, Pomanda has estimated its turnover at £2m with high growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Blumont Pharma Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 3 areas for improvement. Company Health Check FAQs

Health Rating5out of 5

6 Strong

3 Regular

3 Weak

Size

annual sales of £2m, make it smaller than the average company (£16.2m)

Growth

3 year (CAGR) sales growth of 17%, show it is growing at a faster rate (6.3%)

EXPORT

Blumont Pharma Limited's latest turnover from December 2023 is estimated at £2 million and the company has net assets of £788.7 thousand. According to their latest financial statements, Blumont Pharma Limited has 2 employees and maintains cash reserves of £557.8 thousand as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009
Turnover	2,045,661	1,421,160	983,951	1,281,454	974,199	904,840	586,668	818,655	259,852	3,030,465	688,736	1,618,306	548,021	1,858,997
Other Income Or Grants
Cost Of Sales	1,481,212	1,026,606	712,911	933,933	708,382	663,169	426,577	587,902	186,360	2,186,277	495,147	1,160,882	394,708	1,330,705
Gross Profit	564,449	394,554	271,040	347,521	265,817	241,671	160,091	230,752	73,492	844,188	193,590	457,425	153,314	528,292
Admin Expenses	59,850	509,906	109,747	208,852	59,102	203,956	327,299	104,954	51,922	659,743	344	542,264	-54,381	417,236	341,085
Operating Profit	504,599	-115,352	161,293	138,669	206,715	37,715	-167,208	125,798	21,570	184,445	193,246	-84,839	207,695	111,056	-341,085
Interest Payable
Interest Receivable	20,912	8,520	401	190	1,753	1,286	986	317	664	821	543	365	185	209	110
Pre-Tax Profit	525,511	-106,832	161,694	138,859	208,468	39,001	-166,222	126,115	22,234	185,266	193,788	-84,474	207,880	111,265	-340,975
Tax	-131,378		-30,722	-26,383	-39,609	-7,410		-25,223	-4,447	-38,906	-44,571		-54,049	-31,154
Profit After Tax	394,133	-106,832	130,972	112,476	168,859	31,591	-166,222	100,892	17,787	146,360	149,217	-84,474	153,831	80,111	-340,975
Dividends Paid
Retained Profit	394,133	-106,832	130,972	112,476	168,859	31,591	-166,222	100,892	17,787	146,360	149,217	-84,474	153,831	80,111	-340,975
Employee Costs	88,902	84,182	80,502	75,476	37,738	36,955	36,137	176,608	34,346	370,607	100,978	199,184	66,097	226,064
Number Of Employees	2	2	2	2	1	1	1	5	1	11	3	6	2	7
EBITDA*	505,389	-115,008	162,364	139,721	207,773	39,094	-166,726	126,166	22,792	186,499	195,602	-82,438	210,365	113,762	-339,333

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009
Tangible Assets	2,655	3,445	3,199	3,116	3,029	3,517	2,557	677	271	353	1,267	2,482	4,374	5,902	6,410
Intangible Assets			1,424	1,662	1,899	2,172	2,689	578	874	2,014	3,154	4,295	5,435	6,576	7,716
Investments & Other
Debtors (Due After 1 year)											422,798	413,847	424,686	436,846	477,162
Total Fixed Assets	2,655	3,445	4,623	4,778	4,928	5,689	5,246	1,255	1,145	2,367	427,219	420,624	434,495	449,324	491,288
Stock & work in progress	133,363		198,015	206,855	20,283	103,603	29,625	43,688	8,523	115,467	42,729	36,185	18,189	314,409	194,871
Trade Debtors	635,827	406,404	288,390	368,166	308,570	245,232	177,210	155,924	83,508	512,601	51,188	177,924	40,588	280,343	95,681
Group Debtors
Misc Debtors	1,267	1,420	28,988	1,163	3,108	205	691	803	249,190
Cash	557,805	238,831	248,015	72,918	307,227	160,275	182,604	211,812	42,156	223,387	105,105	112,014	34,176	39,764	44,018
misc current assets
total current assets	1,328,262	646,655	763,408	649,102	639,188	509,315	390,130	412,227	383,377	851,455	199,022	326,123	92,953	634,516	334,570
total assets	1,330,917	650,100	768,031	653,880	644,116	515,004	395,376	413,482	384,522	853,822	626,241	746,747	527,448	1,083,840	825,858
Bank overdraft
Bank loan
Trade Creditors	135,965	9,255	6,559	70,933	112,791	124,528	71,365	70,651	7,188	748,752	250,981	529,424	215,071	380,076	72,863
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities	405,562	245,597	259,439	211,902	272,833	300,788	266,049	118,947	254,477
total current liabilities	541,527	254,852	265,998	282,835	385,624	425,316	337,414	189,598	261,665	748,752	250,981	529,424	215,071	380,076	72,863
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities											416,550	407,830	418,410	963,628	1,092,970
provisions	664	655	608	592	515	570	435	135
total long term liabilities	664	655	608	592	515	570	435	135			416,550	407,830	418,410	963,628	1,092,970
total liabilities	542,191	255,507	266,606	283,427	386,139	425,886	337,849	189,733	261,665	748,752	667,531	937,254	633,481	1,343,704	1,165,833
net assets	788,726	394,593	501,425	370,453	257,977	89,118	57,527	223,749	122,857	105,070	-41,290	-190,507	-106,033	-259,864	-339,975
total shareholders funds	788,726	394,593	501,425	370,453	257,977	89,118	57,527	223,749	122,857	105,070	-41,290	-190,507	-106,033	-259,864	-339,975

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009
Operating Activities
Operating Profit	504,599	-115,352	161,293	138,669	206,715	37,715	-167,208	125,798	21,570	184,445	193,246	-84,839	207,695	111,056	-341,085
Depreciation	790	344	833	815	820	862	218	72	82	914	1,215	1,261	1,529	1,565	646
Amortisation			238	237	238	517	264	296	1,140	1,140	1,141	1,140	1,141	1,141	1,106
Tax	-131,378		-30,722	-26,383	-39,609	-7,410		-25,223	-4,447	-38,906	-44,571		-54,049	-31,154
Stock	133,363	-198,015	-8,840	186,572	-83,320	73,978	-14,063	35,165	-106,944	72,738	6,544	17,996	-296,220	119,538	194,871
Debtors	229,270	90,446	-51,951	57,651	66,241	67,536	21,174	-175,971	-179,903	38,615	-117,785	126,497	-251,915	144,346	572,843
Creditors	126,710	2,696	-64,374	-41,858	-11,737	53,163	714	63,463	-741,564	497,771	-278,443	314,353	-165,005	307,213	72,863
Accruals and Deferred Income	159,965	-13,842	47,537	-60,931	-27,955	34,739	147,102	-135,530	254,477
Deferred Taxes & Provisions	9	47	16	77	-55	135	300	135
Cash flow from operations	298,062	-18,538	175,612	-233,597	145,496	-21,793	-25,721	169,817	-181,895	534,011	-16,171	87,422	539,446	125,937	-1,034,184
Investing Activities
capital expenditure		834	-916	-902	-297	-1,822	-4,473	-478				631	-1	-1,058	-15,878
Change in Investments
cash flow from investments		834	-916	-902	-297	-1,822	-4,473	-478				631	-1	-1,058	-15,878
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities										-416,550	8,720	-10,580	-545,218	-129,342	1,092,970
share issue															1,000
interest	20,912	8,520	401	190	1,753	1,286	986	317	664	821	543	365	185	209	110
cash flow from financing	20,912	8,520	401	190	1,753	1,286	986	317	664	-415,729	9,263	-10,215	-545,033	-129,133	1,094,080
cash and cash equivalents
cash	318,974	-9,184	175,097	-234,309	146,952	-22,329	-29,208	169,656	-181,231	118,282	-6,909	77,838	-5,588	-4,254	44,018
overdraft
change in cash	318,974	-9,184	175,097	-234,309	146,952	-22,329	-29,208	169,656	-181,231	118,282	-6,909	77,838	-5,588	-4,254	44,018

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for blumont pharma limited. Get real-time insights into blumont pharma limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for blumont pharma limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other small companies, companies in NG31 area or any other competitors across 12 key performance metrics.

BLUMONT PHARMA LIMITED group structure

Blumont Pharma Limited has no subsidiary companies.

Ultimate parent company

BLUMONT PHARMA LIMITED

05643716

BLUMONT PHARMA LIMITED Shareholders

manoj prabu janaki ponnusamy	90%
jane whitton	10%

Blumont Pharma Limited currently has 5 directors. The longest serving directors include Dr Palaniswamy Sunderraj (Dec 2005) and Ms Jane Whitton (Aug 2007).

officer	country	age	start	end	role
Dr Palaniswamy Sunderraj	England	65 years	Dec 2005	-	Director
Ms Jane Whitton	England	58 years	Aug 2007	-	Director
Mrs Kalpana Sunderraj	United Kingdom	63 years	Dec 2015	-	Director
Manoj Janaki Ponnusamy	England	38 years	Jan 2023	-	Director
Ms Vinitha Gunasekaran	England	31 years	Jan 2025	-	Director

P&L

December 2023

turnover

+44%

operating profit

504.6k

gross margin

27.6%

-0.61%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

December 2023

net assets

788.7k

+1%

total assets

1.3m

+1.05%

cash

557.8k

+1.34%

net assets

Total assets minus all liabilities

Similar Companies

graham roberts plastics limited

multiops limited

metsa board uk limited

2.5

sunbed & leisure systems uk limited

migatronic welding equipment limited

3.5

company number

05643716

Type

Private limited with Share Capital

industry

46900 - Non-specialised wholesale trade

incorporation date

December 2005

ultimate parent company

None

previous names

omnivision pharma limited (July 2007)

address

23 moortown close, grantham, lincolnshire, NG31 9GG

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to blumont pharma limited.

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for BLUMONT PHARMA LIMITED. This can take several minutes, an email will notify you when this has completed.

blumont pharma limited Company Information

blumont pharma limited Estimated Valuation

blumont pharma limited Estimated Valuation

blumont pharma limited Estimated Valuation

Blumont Pharma Limited Overview

Blumont Pharma Limited Health Check

BLUMONT PHARMA LIMITED financials

blumont pharma limited Credit Report and Business Information

Blumont Pharma Limited Competitor Analysis

blumont pharma limited Ownership

blumont pharma limited directors

blumont pharma limited company details

blumont pharma limited Charges & Mortgages

blumont pharma limited Capital Raised & Share Issues BETA

blumont pharma limited Companies House Filings - See Documents